每经头条（nbdtoutiao）——"25基点太少，50基点太多"：美联储降息"走钢丝"，"特朗普代言人"投下唯 一反对票 （记者 张喜威） 每经AI快讯，欧林生物（SH 688319，收盘价：26.8元）9月19日晚间发布公告称，近期，成都欧林生物 科技股份有限公司"重组多重耐药金黄色葡萄球菌疫苗研制与产业化"项目入选四川省2025年第二批省级 科技计划，公司于2025年9月19日收到政府补助款项共计人民币464万元，其中324.8万元为公司所获政 府补助；其余139.2万元为项目合作单位所获政府补助。 2024年1至12月份，欧林生物的营业收入构成为：医药制造业占比99.53%，其他业务占比0.47%。 截至发稿，欧林生物市值为109亿元。 ...

格隆汇9月19日丨欧林生物(688319.SH)公布，公司"重组多重耐药金黄色葡萄球菌疫苗研制与产业化"项 目入选四川省2025年第二批省级科技计划，公司于2025年9月19日收到政府补助款项共计人民币464万 元，其中324.8万元为公司所获政府补助；其余139.2万元为项目合作单位所获政府补助。本次收到的政 府补助将全部计入公司专项应付款科目，并按照相关规定根据项目后续完成及验收情况进行相应会计处 理。公司所获政府补助324.8万元均为与收益相关的政府补助。 ...

格隆汇9月19日丨欧林生物(688319.SH)公布，公司"重组多重耐药金黄色葡萄球菌疫苗研制与产业化"项 目入选四川省2025年第二批省级科技计划，公司于2025年9月19日收到政府补助款项共计人民币464万 元，其中324.8万元为公司所获政府补助；其余139.2万元为项目合作单位所获政府补助。本次收到的政 府补助将全部计入公司专项应付款科目，并按照相关规定根据项目后续完成及验收情况进行相应会计处 理。公司所获政府补助324.8万元均为与收益相关的政府补助。 ...

进一步统计，近3个月内该股累计发生5笔大宗交易，合计成交金额为1962.05万元。 欧林生物9月18日大宗交易平台出现一笔成交，成交量8.70万股，成交金额201.06万元，大宗交易成交价 为23.11元，相对今日收盘价折价15.01%。该笔交易的买方营业部为中信建投证券股份有限公司北京望 京证券营业部，卖方营业部为广发证券股份有限公司成都麓山大道证券营业部。 9月18日欧林生物大宗交易一览 | 成交量 | 成交金额 | 成交价 | 相对当日收盘 | | | | --- | --- | --- | --- | --- | --- | | （万 | （万元） | 格 | 折溢价（%） | 买方营业部 | 卖方营业部 | | 股） | | （元） | | | | | 8.70 | 201.06 | 23.11 | -15.01 | 中信建投证券股份有限公 | 广发证券股份有限公司成 | | | | | | 司北京望京证券营业部 | 都麓山大道证券营业部 | 注：本文系新闻报道，不构成投资建议，股市有风险，投资需谨慎。 （文章来源：证券时报网） 证券时报·数据宝统计显示，欧林生物今日收盘价为27.19元，下跌3.1 ...

| 交易日期 | 证券简称 | 证券代码 | 成交价(元) 成交金额(万元) 成交量( * ) 买入营业部 | | | 卖出营业部 | | --- | --- | --- | --- | --- | --- | --- | | 2025-09-18 | 欧林生物 | 688319 | 23.11 201.06 | 8.7 | 中信建投证券股份 | 广发证券股份有限 | | | | | | | 有限公司北京望京 | 公司成都麓山大道 | | | | | | | 1 7 4 2 2 1 . 40 | ST 44 22 . 1 . 40 | 9月18日，欧林生物大宗交易成交8.7万股，成交额201.06万元，占当日总成交额的0.57%，成交价23.11元，较市场收盘价27.19元折价15.01%。 ...

Group 1 - The core viewpoint of the news is the performance and financial details of Olin Bio, which saw a stock price increase of 5.3% to 28.40 CNY per share, with a total market capitalization of 11.529 billion CNY [1] - Olin Bio, established on December 11, 2009, specializes in the research, production, and sales of human vaccines, with the majority of its revenue coming from the adsorbed tetanus vaccine at 90.99% [1] - The company also generates revenue from other vaccines, including A group and C group meningococcal polysaccharide conjugate vaccine (4.49%), b-type Haemophilus influenzae type b conjugate vaccine (3.99%), and others [1] Group 2 - From the perspective of fund holdings, Olin Bio is a significant investment for the Fuyong Fund, with its Fuyong Medical Health Mixed Fund A (015655) holding 17,200 shares, representing 2.06% of the fund's net value [2] - The fund has seen a year-to-date return of 14.22% and a one-year return of 10.55%, although it has experienced a loss of 20.8% since its inception [2]

Core Insights - The innovation drug industry in China is experiencing significant advancements in product research and development, with companies actively discussing their progress and strategies during the recent performance briefing session [1][2][3]. Group 1: Product Innovation and R&D Progress - Companies like Fudan Zhangjiang and Olin Bio are making notable advancements in their product pipelines, focusing on photodynamic therapy and vaccines for "super bacteria" [1][2]. - Fudan Zhangjiang is developing several drugs targeting conditions such as severe acne and bladder cancer, with ongoing clinical studies [2]. - Olin Bio is researching multiple vaccines for "super bacteria," aiming to initiate clinical trials for flu vaccines by mid-2025 [2]. Group 2: Business Expansion and Market Strategy - Companies are planning to expand their production capacity to support product commercialization, with Baiyao Tai focusing on launching several products that have completed Phase III clinical trials [3][4]. - Shian Bio is set to contribute significant revenue from its various vaccine products, including those for swine fever and other diseases [4]. Group 3: Internationalization and Market Entry - The trend of "going global" is a major focus for the domestic biopharmaceutical industry, with companies exploring diverse international pathways [5]. - Yuantong Bio is awaiting FDA approval for its naloxone nasal spray, marking a step towards international market entry [5]. - Aidi Pharmaceutical has received regulatory approval for its HIV treatment in Zanzibar, highlighting its international expansion efforts [6]. - Companies like Ailis and Haichuang Pharmaceutical are actively pursuing overseas partnerships and clinical trials to enhance their global presence [6][7].

Core Viewpoint - The company, Chengdu Olin Biological Technology Co., Ltd., is focusing on enhancing its market position through medical education and product promotion while advancing its vaccine research and clinical trials for Staphylococcus aureus and influenza vaccines [1][2]. Financial Performance - In the first half of 2025, the company achieved a revenue of 306 million yuan, representing a year-on-year growth of 35.17% [1]. - The net profit attributable to shareholders was 13.2 million yuan, with a net profit of 7.72 million yuan after deducting non-recurring gains and losses, marking a turnaround from losses in the previous year [1]. R&D Pipeline - The company is focusing on two strategic directions: "super bacteria" vaccines and "adult vaccines," continuously enriching its pipeline and enhancing innovation capabilities [2]. - The company is researching four "super bacteria" vaccines, including recombinant Staphylococcus aureus vaccine, oral recombinant Helicobacter pylori vaccine, recombinant Pseudomonas aeruginosa vaccine, and recombinant Acinetobacter baumannii protein vaccine, all classified as global Class 1 new drugs [2]. Clinical Trials - The recombinant Staphylococcus aureus vaccine has completed Phase I and II clinical trials, with Phase III trials currently ongoing and leading globally [2]. - The vaccine aims to prevent Staphylococcus aureus infections post-surgery, with no similar products available globally, indicating a broad application potential in hospital infection prevention [3]. - The company’s Helicobacter pylori vaccine received Phase I clinical trial approval in Australia in 2024, and further optimization of the oral formulation is underway for future domestic clinical trial applications [3]. Technological Advancements - The company is expanding its technological platforms and has made significant progress in the field of viral vaccines, having initiated Phase I clinical trials for trivalent and quadrivalent influenza virus split vaccines in the first half of 2025 [3].

人民财讯9月9日电，9月8日，成都欧林生物科技股份有限公司与江苏省疾病预防控制中心在成都正式签 署战略合作框架协议。此次合作聚焦疫苗研发、疾病防控、公共卫生能力建设三大核心领域，旨在推动 科研创新、人才储备、医防融合与健康服务协同发展，重点推进创新疫苗临床研究与评价、成人接种服 务体系优化及区域传染病防控技术升级。 ...

Core Viewpoint - Oulin Biotech has shown significant stock performance with a year-to-date increase of 169.43%, despite a recent slight decline in the last five trading days [1] Group 1: Stock Performance - As of September 9, Oulin Biotech's stock price reached 28.56 CNY per share, with a market capitalization of 11.593 billion CNY [1] - The stock has experienced a 1.07% decline over the last five trading days, but a 39.32% increase over the last 20 days and a 76.62% increase over the last 60 days [1] - The company has appeared on the "龙虎榜" (top trading list) twice this year, with the latest occurrence on August 20 [1] Group 2: Financial Performance - For the first half of 2025, Oulin Biotech reported a revenue of 306 million CNY, representing a year-on-year growth of 35.17% [2] - The net profit attributable to shareholders for the same period was 13.197 million CNY, showing a substantial increase of 147.22% year-on-year [2] Group 3: Shareholder Information - As of June 30, 2025, the number of shareholders increased by 4.86% to 6,521, while the average number of circulating shares per person decreased by 4.63% to 62,169 shares [2] - The company has distributed a total of 15.434 million CNY in dividends since its A-share listing [3] - Among the top ten circulating shareholders, "兴全合润混合A" holds 15.4402 million shares, while "兴全合宜混合A" holds 8.9214 million shares, with both maintaining their holdings from the previous period [3]